Rhythm Pharmaceuticals (RYTM) Share-based Compensation (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Share-based Compensation data on file, last reported at $23.1 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $23.1 million, up 79.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.1 million (up 72.09% YoY), and the FY2025 annual result was $66.8 million, up 68.38% from the prior year.
• Share-based Compensation advanced to $23.1 million in Q1 2026 per RYTM's latest filing, from $19.3 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $23.1 million in Q1 2026 and troughed at $4.6 million in Q1 2022.
• A 5-year average of $10.7 million and a median of $8.9 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation decreased 11.17% in 2022, then jumped 82.51% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $5.3 million in 2022, then surged by 64.06% to $8.7 million in 2023, then grew by 21.7% to $10.6 million in 2024, then jumped by 82.51% to $19.3 million in 2025, then advanced by 19.9% to $23.1 million in 2026.
• Business Quant data shows RYTM's Share-based Compensation at $23.1 million in Q1 2026, $19.3 million in Q4 2025, and $18.8 million in Q3 2025.